论文部分内容阅读
目的更新欧洲泌尿生殖放射协会(ESUR)的对比剂安全委员会(CMSC)关于肾源性系统性纤维化(NSF)及钆对比剂的指导方针。涉及内容审查内容包括病史、临床表现及肾源性系统性纤维化的发病率和目前对其病理生理学的了解。讨论引起NSF的风险因素并推荐预防措施。对不同钆对比剂的稳定性和钆对人体潜在的长期影响也进行了研究。要点①回顾肾NSF的临床特征、危险因素及预防措施。②病人肾小球滤过率低于30mL/(min·1.73m2)时可增加NSF发生的危险性。③低稳定性钆对比剂与NSF的发生具有显著相关性。④遵循钆对比剂指导方针最大程度地降低了NSF的风险。⑤讨论了钆在人体蓄积潜在的长期危害。
Objectives To update guidelines from the Contraceptive Safety Commission (ESC) of the European Genitourinary Association (ESUR) on nephrogenic systemic fibrosis (NSF) and gadolinium contrast agents. Content reviews include medical history, clinical manifestations, and incidence of nephrogenic systemic fibrosis and current knowledge of their pathophysiology. Discuss the risk factors that cause NSF and recommend preventive measures. The stability of different gadolinium contrast agents and the potential long-term effects of gadolinium on humans have also been investigated. Points ① review of renal NSF clinical features, risk factors and preventive measures. ② patients with glomerular filtration rate less than 30mL / (min · 1.73m2) can increase the risk of NSF. ③ low stability of gadolinium contrast agent and the occurrence of NSF has a significant correlation. Follow the guidelines for gadolinium contrast agents to minimize the risk of NSF. ⑤ Discussed the potential long-term harm of gadolinium in the human body.